Jarrett Burks

Jarrett Burks is an associate in our corporate practice where he counsels clients on a range of matters, with an emphasis on mergers and acquisitions and capital markets. He has advised a range of public and private companies across multiple industries, including technology, life sciences, financial institutions, consumer and industrials.

Prior to joining Cooley, Jarrett was an associate at Cravath, Swaine & Moore LLP in both their New York and London offices.

His recent experience include advising:

• Alvotech Holdings, a biopharmaceutical company, on its agreement to merge with special purpose acquisition company (SPAC) Oaktree Acquisition Corp. II, with the combined company valued at $2.25 billion
• Athenx, a biopharmaceutical company dedicated to the discovery, development, and commercialisation of novel therapies for the treatment of cancer and related conditions, on its $185 million acquisition of Kuur Therapeutics
• Bavarian Nordic, a vaccine company, has entered into a definitive agreement to acquire Emergent BioSolutions’ travel vaccines portfolio for up to $380 million, including an upfront payment of $270 million
• biote, a hormone optimisation company, on its agreement to merge with special purpose acquisition company (SPAC) Haymaker Acquisition Corp. III, with the combined company valued at $737 million
• Oculis, a global biopharmaceutical company, on its agreement to combine with European Biotech Acquisition (a SPAC) for $248 million
• The DKK2.7 billion Rights Offering of Bavarian Nordic on the Nasdaq Copenhagen
• ZOLL Medical Corporation, manufacturer of medical devices on its definitive agreement to acquire Itamar Medical, a digital health company focused on sleep apnea diagnosis, for a total value of $538 million